Filter by:
- All
- AGM
- AM24
- announcement
- Annual General Meeting
- Annual Meeting
- Asia Policy Fora
- Asia Policy Forum
- awards
- Board
- Board and Committees
- Board Election
- Board of Director
- Board of Directors
- Citizens
- Committee
- committees
- competency
- DCIG
- Deadline
- edihta
- education
- Election
- europe
- European Commission
- External event
- Favorites
- Featured
- Funding
- Global Policy Fora
- Global Policy Forum
- Hospital based
- HTA
- Interest Group
- Interest Groups
- Interest Groups a
- LATAM
- LATAM Policy Forum
- latin america
- Latin America Policy Fora
- Latin America Policy Forum
- leadership
- Learn with us
- Medical Devices
- membership
- MENA
- Milestone
- msc
- news
- nominations
- Not for Profit
- opportunity
- Organizing Committee
- parternship
- Participation Grant
- Participation Grants
- partner
- Partners
- Patients
- PCIG
- Policy Fora
- Policy Forum
- Rare Disease
- rare diseases
- rare webinar
- RDIG
- Regional
- Regional Meeting
- Regulations
- RWE&AI
- scholarships
- steering committee
- technical officer
- Upcoming Event
- updates
- vacancy
- Webinar
- webinar rare disease
- World Health
HTAi Webinar | Why do we need a New Paradigm for Evidence Generation and Assessment in Rare Disease Technologies
This multi-stakeholder webinar explores challenges in evidence generation for rare disease technologies (RDTs) and the impacts this has for assessment in HTA, and how to…
Read Moreabout HTAi Webinar | Why do we need a New Paradigm for Evidence Generation and Assessment in Rare Disease Technologies
HTAi Webinar: The Characteristics of Rare Diseases That Complicate the Assessment of Technology Value
This HTAi Webinar is hosted by the HTAi Rare Diseases Interest Group. Evaluating the value of rare disease technologies poses challenges due to factors like…
Read Moreabout HTAi Webinar: The Characteristics of Rare Diseases That Complicate the Assessment of Technology Value
HTAi Webinar | HTA in Childhood Diseases
Treatments for childhood diseases are challenging to study in terms of enrolment in clinical trials, availability of valid outcome measures and instruments of assessment and…
Read Moreabout HTAi Webinar | HTA in Childhood Diseases